AccessibilityHelpAbout Us
PureTech Health Plc logo

PureTech Health Plc(OTC) PTCHF

Market Cap$377.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-36%
5 Year-69%
1 Year-1%
1 Month-2%
$1.54
+0.00%
+0.00Today
PureTech Health Plc last closing stock price
MetricPriceDate
Last closeUSD 1.542026-09-23
PureTech Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.63%USD 1.652026-09-08
1 month-1.5%USD 1.562026-08-06
3 month-9.35%USD 1.702026-06-11
Year to date-9.62%USD 1.712025-12-29
1 year-0.58%USD 1.552025-09-22
3 year-41.45%USD 2.632023-09-22
5 year-68.62%USD 4.912021-09-24
Since inception-35.52%USD 2.392015-07-29

PureTech Health Plc Financials at a Glance

Market Cap

$377.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.21M

Net Income (TTM)

$51.43M

EPS (TTM)

$0.00

P/E Ratio

217.04

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$1.54

Volume

500

Open

$1.54

Previous Close

$1.54

Daily Range

$1.54 - $1.54

52-Week Range

$1.53 - $1.92

Estimated Earnings Date

Apr 29, 2027

PTCHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PureTech Health Plc

PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, focusing on the discovery and advancement of innovative therapeutic solutions. The company targets a diverse range of challenging medical conditions, including inflammatory disorders, cancers, and neurological ailments.

Products and Services
  • KarXT for managing schizophrenia and Alzheimer's-related psychosis
  • Regenerative biology platform for conditions like androgenetic alopecia
  • Immunomodulation platform for chronic inflammatory disorders
Growth Outlook
  • Pipeline includes LYT-100 for lymphedema and LYT-200 targeting galectin-9
  • Key collaborations with major pharmaceutical companies enhance development capabilities
  • Innovative platforms like Orasome technology enable oral delivery of complex medications
Financial Highlights
  • Recent quarterly revenue of $3.51 million, showing growth from previous quarters
  • Net income of $66.27 million in the latest quarter, indicating strong operational performance
  • Cash and short-term investments total $221.1 million, providing a solid financial foundation
PureTech Health plc is positioned in the biotechnology sector, with a focus on addressing unmet medical needs through its innovative product pipeline. The company has made significant strides in its research and development efforts, evidenced by its collaborations with leading pharmaceutical firms. Recent financial performance highlights a positive trajectory, with increasing revenue and a robust cash position, which may support future growth initiatives. The diverse range of therapeutic solutions under development reflects the company's commitment to advancing healthcare and improving patient outcomes.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert William Henry Lyne

Website

puretechhealth.com

Headquarters

Boston, MA 02210, US

PTCHF Financials

Key Financial Metrics (TTM)

Gross Margin

48.09%

Operating Margin

-1618.58%

Net Income Margin

7.53%

Return on Equity

0.14%

Return on Capital

-30.30%

Return on Assets

0.07%

Earnings Yield

0.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$377.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

245.18M

Volume

500

Avg. Volume

1.04K

Financials (TTM)

Gross Profit

$46.18M

Operating Income

-$221.96M

EBITDA

-$45.25M

Operating Cash Flow

-$182.01M

Capital Expenditure

-$17.04K

Free Cash Flow

-$182.03M

Cash & ST Invst.

$221.10M

Total Debt

$18.45M

PureTech Health Plc Performance Analysis

PureTech Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 15,618,000-10.2%
20232023-12-31USD 3,330,000-78.7%
20242024-12-31USD 4,828,00045.0%
20252025-12-31USD 4,659,000-3.5%
PureTech Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311298.3%
Q22025-06-30-54.0%
Q42025-12-3152.6%
Q22026-06-3024.1%
PureTech Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.18-16.3%
20232023-12-31USD -0.2434.5%
20242024-12-31USD 0.21N/A
20252025-12-31USD -0.46N/A
PureTech Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31333.3%
Q22025-06-30-154.3%
Q42025-12-31-47.4%
Q22026-06-30196.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.51M

+1117.2%

Gross Profit

$1.89M

+104.9%

Gross Margin

53.81%

N/A

Market Cap

$377.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.72M

N/A

Employees

80

N/A

Net Income

$66.27M

+258.7%

EBITDA

-$49.93M

+22.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$221.10M

-55.8%

Total Debt

$18.45M

-23.2%

Accounts Receivable

$8.52M

+314.4%

Inventory

$0.00

+100.0%

Long Term Debt

$9.15M

-44.3%

Short Term Debt

$9.30M

+22.4%

Return on Assets

0.07%

N/A

Return on Invested Capital

-17.44%

N/A

Free Cash Flow

-$43.80M

+45.3%

Operating Cash Flow

-$43.80M

+45.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLVLFClinuvel Pharmaceuticals Limited
$5.68-3.57%
NWBONorthwest Biotherapeutics, Inc.
$0.16+0.00%
BOVNFBioInvent International AB (publ)
$3.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About PTCHF

What is the current price of PureTech Health Plc?

PureTech Health Plc is trading at $1.54 per share.

What is the 52-week range for PureTech Health Plc?

Over the past 52 weeks, PureTech Health Plc has traded between $1.53 and $1.92.

How much debt does PureTech Health Plc have?

As of the most recent reporting period, PureTech Health Plc reported total debt of $19.76M.

How much cash does PureTech Health Plc have on hand?

PureTech Health Plc reported $254.07M in cash and cash equivalents in its most recent financial results.

What is PureTech Health Plc’s dividend yield?

PureTech Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services